Dimethaid WF10 fails Phase III for HIV
This article was originally published in Pharmaceutical Approvals Monthly
Dimethaid is halting development of its HIV/AIDS agent WF10 following the immune regulator's failure to meet primary endpoints in a 96-week, placebo-controlled, double-blind Phase III trial. Results from the North American trial's 229 late-stage AIDS patients "indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death," the firm says July 14. Dimethaid plans to evaluate the study's secondary results and "re-evaluate WF10's future business potential and its position in the company's long-term development pipeline." The firm notes WF10 (tetrachlorodecaoxygen) may have potential in autoimmune diseases and oncology...
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.